USPIOs as Targeted Contrast Agents in Cardiovascular Magnetic Resonance Imaging
Authors:
- 26 February 2021
- journal article
- research article
- Published by Springer Nature in Current Cardiovascular Imaging Reports
- Vol. 14 (2) , 1-10
Abstract
Purpose of Review We aim to discuss the diagnostic use of ultrasmall superparamagnetic iron oxide (USPIO) including ferumoxytol in targeted cardiovascular magnetic resonance imaging (MRI). Recent Findings Ferumoxytol is the only USPIO clinically available in the USA and is a negatively charged USPIO that has potential use for tracking and characterization of macrophage-infiltrated cardiovascular structures. As an iron supplement that is approved for treatment of iron deficiency anemia, the iron core of ferumoxytol is incorporated into the body once it is phagocytosed by macrophages. In organs or tissues with high-inflammatory cellular infiltration, such as atherosclerotic plaques and myocardial infarction, localization of iron-laden macrophages can be visualized on delayed MRI. The iron core of ferumoxytol alters the magnetic susceptibility and results in shortening of T2* and T2 relaxation rates. Areas with high concentration appear hypointense (negative contrast) on T2 and T2* MRI. Recently, in vitro findings support the potential specificity of ferumoxytol interactions with macrophage subtypes, which has implications for therapeutic interventions. With increasing concerns about gadolinium retention in the brain and other tissues, the value of ferumoxytol-enhanced MR for targeted clinical imaging is aided by its positive safety profile in patients with impaired renal function. Summary This paper discusses pharmacokinetic properties of USPIOs with a focus on ferumoxytol, and summarizes relevant in vitro, animal, and human studies investigating the diagnostic use of USPIOs in targeted contrast-enhanced imaging. We also discuss future directions for USPIOs as targeted imaging agents and associated challenges.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (R01HL148182)
- U.S. Department of Veterans Affairs (I01-CX001901)
This publication has 55 references indexed in Scilit:
- Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: a human study using a multi-parametric cardiovascular magnetic resonance imaging approachEuropean Heart Journal, 2012
- FerumoxytolDrugs, 2012
- Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients With Acute Myocardial InfarctionCirculation: Cardiovascular Imaging, 2012
- Noninvasive Assessment of Myocardial Inflammation by Cardiovascular Magnetic Resonance in a Rat Model of Experimental Autoimmune MyocarditisCirculation, 2012
- Abdominal Aortic Aneurysm Growth Predicted by Uptake of Ultrasmall Superparamagnetic Particles of Iron OxideCirculation: Cardiovascular Imaging, 2011
- Ultrasmall Superparamagnetic Iron Oxide-enhanced Magnetic Resonance Imaging of Abdominal Aortic Aneurysms–A Feasibility StudyEuropean Journal of Vascular and Endovascular Surgery, 2011
- The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) StudyJACC, 2009
- Utility of USPIO-enhanced MR imaging to identify inflammation and the fibrous cap: A comparison of symptomatic and asymptomatic individualsEuropean Journal of Radiology, 2009
- Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic EvaluationJACC, 2009
- Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance ImagingCirculation, 2003